On Tuesday, Intra-Cellular Therapies Inc (NASDAQ: ITCI) opened higher 3.56% from the last session, before settling in for the closing price of $86.17. Price fluctuations for ITCI have ranged from $52.88 to $88.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 7617.73%. Company’s average yearly earnings per share was noted 58.05% at the time writing. With a float of $99.09 million, this company’s outstanding shares have now reached $106.02 million.
Considering the fact that the conglomerate employs 610 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 92.29%, operating margin of -19.84%, and the pretax margin is -13.89%.
Intra-Cellular Therapies Inc (ITCI) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Intra-Cellular Therapies Inc is 6.53%, while institutional ownership is 91.78%. The most recent insider transaction that took place on Sep 06 ’24, was worth 1,829,178. Before that another transaction happened on Aug 29 ’24, when Company’s Chairman and CEO sold 35,604 for $72.57, making the entire transaction worth $2,583,884. This insider now owns 1,070,329 shares in total.
Intra-Cellular Therapies Inc (ITCI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 58.05% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Check out the current performance indicators for Intra-Cellular Therapies Inc (ITCI). In the past quarter, the stock posted a quick ratio of 7.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach 0.48 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Compared to the last year’s volume of 0.87 million, its volume of 1.15 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 91.26%. Additionally, its Average True Range was 2.58.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 99.14%, which indicates a significant increase from 98.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.66% in the past 14 days, which was higher than the 35.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $75.73, while its 200-day Moving Average is $72.12. Nevertheless, the first resistance level for the watch stands at $90.76 in the near term. At $92.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $95.12. If the price goes on to break the first support level at $86.40, it is likely to go to the next support level at $83.56. Should the price break the second support level, the third support level stands at $82.04.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
There are currently 106,017K shares outstanding in the company with a market cap of 9.46 billion. Presently, the company’s annual sales total 464,370 K according to its annual income of -139,670 K. Last quarter, the company’s sales amounted to 175,380 K and its income totaled -26,320 K.
